Search research articles
Contact Us
Filters
Showing results (321-330 of 447) with videos related to
Page
of 45
Sort By:
Plos One
|
August 31, 2021
Correction: Molecular basis for a new bovine model of Niemann-Pick type C disease
Shernae A Woolley, Emily R Tsimnadis, Cor Lenghaus, et al.
Plos One
|
September 24, 2020
Molecular basis for a new bovine model of Niemann-Pick type C disease
Shernae A Woolley, Emily R Tsimnadis, Cor Lenghaus, et al.
Nature Methods
|
May 26, 2015
Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture
Anca M Paşca, Steven A Sloan, Laura E Clarke, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
September 2, 2006
Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424
Leslee J Shaw, Gary V Heller, Paul Casperson, et al.
Circulation. Cardiovascular Quality and Outcomes
|
July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology
|
July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
David J Maron, William E Boden, John A Spertus, et al.
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Journal of the American College of Cardiology
|
September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial
Koon K Teo, Steven P Sedlis, William E Boden, et al.
Page
of 45
Search research articles
Search
Showing results (321-330 of 447) with videos related to
Sort By:
Page
of 45
Plos One
|
August 31, 2021
Correction: Molecular basis for a new bovine model of Niemann-Pick type C disease
Shernae A Woolley, Emily R Tsimnadis, Cor Lenghaus, et al.
Plos One
|
September 24, 2020
Molecular basis for a new bovine model of Niemann-Pick type C disease
Shernae A Woolley, Emily R Tsimnadis, Cor Lenghaus, et al.
Nature Methods
|
May 26, 2015
Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture
Anca M Paşca, Steven A Sloan, Laura E Clarke, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
September 2, 2006
Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424
Leslee J Shaw, Gary V Heller, Paul Casperson, et al.
Circulation. Cardiovascular Quality and Outcomes
|
July 29, 2010
Do major cardiovascular outcomes in patients with stable ischemic heart disease in the clinical outcomes utilizing revascularization and aggressive drug evaluation trial differ by healthcare system?
Bernard R Chaitman, Pamela M Hartigan, David C Booth, et al.
Journal of the American College of Cardiology
|
July 2, 2011
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial
David J Maron, William E Boden, John A Spertus, et al.
The American Journal of Cardiology
|
July 7, 2009
Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)
William E Boden, Robert A O'Rourke, Koon K Teo, et al.
The American Journal of Cardiology
|
October 6, 2009
Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
David J Maron, John A Spertus, G B John Mancini, et al.
Circulation. Cardiovascular Interventions
|
November 3, 2011
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial
G B John Mancini, Pamela M Hartigan, Eric R Bates, et al.
Journal of the American College of Cardiology
|
September 26, 2009
Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial
Koon K Teo, Steven P Sedlis, William E Boden, et al.
Page
of 45